FDA clears AstraZeneca's Imfinzi-Padcev combo for muscle-invasive bladder cancer
AstraZeneca won FDA approval for its Imfinzi and Padcev combination in muscle-invasive bladder cancer, aimed at patients who can't tolerate or refuse cisplatin chemotherapy. The priority-review green light rests on the VOLGA trial, where the perioperative regimen cut the risk of progression, recurrence or death by 49%.
- Original source: yahoo.com.
- The source published it on Nov 16, 2026 at 2:36 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The US Food and Drug Administration approved AstraZeneca's Imfinzi (durvalumab) alongside Padcev (enfortumab vedotin) for adults with muscle-invasive bladder cancer who cannot receive or have turned down cisplatin-based chemotherapy. The clearance came under priority review and covers a regimen built with Astellas Pharma and Pfizer's Padcev.
The schedule runs in two stages: neoadjuvant treatment before radical cystectomy, then single-agent Imfinzi as adjuvant therapy afterward. It leans on the multi-centre VOLGA Phase III study, published in The New England Journal of Medicine and presented at the 2026 European Society for Medical Oncology Congress.
In the 695-patient trial, the perioperative regimen reduced the risk of disease progression, recurrence, omitted surgery or death by 49% versus radical cystectomy with or without approved adjuvant treatment. Two-year event-free survival landed at an estimated 64%, against 45% in the control arm, where median event-free survival was 12.1 months. Overall survival showed a 42% drop in the risk of death, with two-year rates of 78% versus 69%.
Grade 3 and 4 adverse events from any cause hit 64% of patients on the combination, compared with 44% in the comparator arm. No new safety signals turned up, and patient-reported quality of life held steady after surgery.
Dave Fredrickson, executive vice president of AstraZeneca's oncology haematology business unit, said the approval offers a regimen that almost halved recurrence risk and cut death risk by 42% in VOLGA. He called it the company's third bladder cancer indication in two years, reinforcing Imfinzi as an immunotherapy backbone across muscle-invasive and non-muscle-invasive disease.
Muscle-invasive tumours make up roughly a quarter of bladder cancer cases, with about 16,000 people in the US expected to receive treatment in 2026. Up to 50% of patients can't tolerate cisplatin because of impaired renal function or other comorbidities, leaving radical cystectomy as the long-standing standard despite frequent recurrences. AstraZeneca's May approval paired Imfinzi with Bacillus Calmette-Guérin for BCG-naïve, high-risk non-muscle-invasive cases, and filings based on the VOLGA trial remain under review in the European Union, Japan and other territories.
TopicsAstraZeneca · Imfinzi · Padcev · FDA · Astellas Pharma · Pfizer · Dave Fredrickson · VOLGA trial
Source: yahoo.com
Written by AI from verified reporting.
More stories
- Health & science finance.yahoo.com 0 viewsNovartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
- Health & science casrai.org 0 viewsFDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
- Health & science nbcnews.com Caught by @nina.anggraini29 0 viewsMeasles Is Endemic Again as the U.S. Loses Its Elimination Status
- Health & science aol.com 1 viewFDA Clears FoundationOne Liquid CDx as First Companion Test for WILSERDLY Combo

